•   
  •   
  •   

Health First person to receive experimental coronavirus vaccine says she learned about the trial on Facebook and had to sign a 45-page waiver before she could receive the shot - as it's revealed participants will be paid just over $1000

14:46  19 march  2020
14:46  19 march  2020 Source:   dailymail.co.uk

Canada's Ebola vaccine almost didn't happen, new study reveals

  Canada's Ebola vaccine almost didn't happen, new study reveals Dalhousie University professor Matthew Herder accessed hundreds of government documents to find out what really happened as Canadian scientists tried for years to get the pharmaceutical industry interested in their discovery of an Ebola vaccine.Dalhousie University law professor Matthew Herder used Canada's Access to Information Act to obtain hundreds of documents to track the development of the vaccine (rVSV-ZEBOV) from the first experiments at Winnipeg's National Microbiology Laboratory in the early 2000s through to the Ebola epidemic in West Africa in 2014.

First person to receive experimental coronavirus vaccine says she learned about the trial on Facebook and had to sign a 45 - page waiver 'We don't know whether this vaccine will induce an immune response, or whether it will be safe. That´ s why we´re doing a trial ,' Jackson stressed.

The very first person to receive this shot was Jennifer Haller from Seattle, a 43-year-old operations manager at a small tech company, and the parent to two teens. She doesn’t have the virus, but she volunteered to take part in the trial in order to help fight the disease. She spoke over the phone to

The first person to receive the first shot in a test of an experimental coronavirus vaccine Monday said that she heard about the trial through a Facebook post.

Mom-of-two, Jennifer Haller, 43, of Seattle, Washington, told Refinery 29 that she heard about the vaccine trial about two weeks ago, when Kaiser Permanente Washington Health Research Institute 'put out a call for volunteers.'

'A friend of mine posted it on Facebook, and I was looking for something to do that could be helpful, so I immediately filled out the survey. The next day I got a phone call to review my health history,' Haller said. 

7 Things That Could Happen If You Sleep on an Old Mattress

  7 Things That Could Happen If You Sleep on an Old Mattress Dealing with poor sleep? It could be time to change your mattress. Here are a few things that could happen if you sleep on an old mattress. The post 7 Things That Could Happen If You Sleep on an Old Mattress appeared first on Best Health Magazine Canada.

He said it is hoped that the Russian vaccine will go into general circulation by January, but in the meantime medical workers and teachers will However, Vadim Tarasov, a top scientist at Moscow’ s Sechenov University, where the trials took place said the country had a head start as it has spent

Medical workers could begin receiving the drug by the end of the month, Deputy Prime Minister Tatyana Golikova said at the meeting. It had over 27,000 coronavirus -related deaths in the second quarter The speed with which the vaccine has received regulatory approval has drawn criticism

'I passed all those qualifications, and went in the next day to do a physical exam, a blood draw, and get more into my health history. And apparently, it was all good and then I got the call to get the first vaccine' on Monday morning. 

Before she could get the vaccine, however, she said that she had to sign a 45-page waiver. 

a person posing for the camera: Jennifer Haller, 43, became the first person to receive a trial coronavirus vaccine injection Monday in Seattle, Washington. She volunteered after hearing about the trial on Facebook © Provided by Daily Mail Jennifer Haller, 43, became the first person to receive a trial coronavirus vaccine injection Monday in Seattle, Washington. She volunteered after hearing about the trial on Facebook

'This has never been tested on humans, so there’s a complete unknown,' she said. 

'I Wasn't Scared': The First Person To Test The Coronavirus Vaccine

  'I Wasn't Scared': The First Person To Test The Coronavirus Vaccine Jennifer Haller, 43, from Seattle doesn’t have the virus, but she volunteered to take part in the trial in order to help fight the disease. Pictures: Coronavirus (COVID-19) outbreak around the world 1/131 SLIDES © Ciro De Luca/Reuters A soldier guides passengers arriving from Turin and Milan by train at the Naples Central station as they wait to get their self-certification documents checked, in Italy on March 22. 2/131 SLIDES © Eduardo Munoz/Reuters A man walks around a local park in Weehawken, New Jersey, U.S., on March 22.

In May, it reported that the first person in the world to be vaccinated against the virus was a Russian researcher who had injected himself even before monkey trials had been completed. If Russian scientists have taken an unorthodox route to the coronavirus vaccine , it would not be the first time.

The first clinical trials on coronavirus vaccines started in March, and now there are 29 If a vaccine is effective, fewer vaccinated volunteers will get sick than the ones who received the placebo. They have addressed the possibility that the vaccine could actually make people prone to worse cases of

  First person to receive experimental coronavirus vaccine says she learned about the trial on Facebook and had to sign a 45-page waiver before she could receive the shot - as it's revealed participants will be paid just over $1000 © Provided by Daily Mail

Haller said that while the trial is 'offering money,' financial remuneration wasn't the motive behind her volunteering. 

According to the trial's study volunteer information page, participants will receive $100 per each in-person study visit and those that complete all visits will be paid a total of $1,100.  

'If I was doing it for money like you couldn’t really pay me enough to do this. So it’s just a token, and it’s not really a driver for me at all,' she said. 

Can you become immune to the coronavirus?

  Can you become immune to the coronavirus? Can you become immune to the coronavirus?The answer is a qualified yes, with some significant unknowns. That’s important for several reasons.

Russia approved a vaccine that has yet to complete clinical trials . Russia approves a vaccine before it completed Phase 3 tests, prompting alarm from experts. The first case in the new cluster was a person living in South Auckland who had no history of traveling abroad, he said .

It is possible a coronavirus vaccine will be proven effective before the end of the year, however, it will not be widely available. More traditional methods of vaccine development are also being investigated. The company Valneva is taking the whole coronavirus , inactivating it and then inject it .

She pointed out that she and her family 'have the resources we need to weather this' and noted that 'I have a deep concern for so many Americans that don’t have the privilege that my family and I have.'

Haller, an operations manager at a small tech company, said that while she was able to go to Costco and buy supplies that her family can use over the next few weeks.

'And even that simple act, a lot of people can’t do that,' she said. 'People are losing their jobs, especially in the restaurant industry, the arts community. It’s devastating, and it’s going to be devastating.'

She said that she is also worried about 'the physical health impact for people and also the mental health impact it’s going to have.'

Haller said that although her friends 'were definitely concerned' about her signing up for the trial, she said that she 'wasn't scared.'

a man standing in front of a computer: Dr Lisa Jackson is leading the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, which was given to the first volunteer in the study by injection, Monday © Provided by Daily Mail Dr Lisa Jackson is leading the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, which was given to the first volunteer in the study by injection, Monday a person sitting at a desk in an office © Provided by Daily Mail

'My understanding is that it’s similar to what they’ve done with MERS and SARS, and that the good that can come from it is so much greater than anything that can happen to me, even if it was the worst,' she told Refinery 29.

Infected but Feeling Fine: The Unwitting Coronavirus Spreaders

  Infected but Feeling Fine: The Unwitting Coronavirus Spreaders As many as 25 percent of people infected with the new coronavirus may not show symptoms, the director of the Centers for Disease Control and Prevention warns — a startlingly high number that complicates efforts to predict the pandemic’s course and strategies to mitigate its spread. In particular, the high level of symptom-free cases is leading the C.D.C. to consider broadening its guidelines on who should wear masks. “This helps explain howIn particular, the high level of symptom-free cases is leading the C.D.C. to consider broadening its guidelines on who should wear masks.

Russia claims it will approve world' s first coronavirus vaccine . It will be approved for public use, with frontline healthcare workers getting it first , they said . Unlike most vaccines in development it relies on two vectors, not one , and patients would receive a second booster shot .

The FMBA has two teams — in Moscow and Saint Petersburg — working simultaneously on the project. "I would like to tell you about the development of the The development of the vaccine has gone through the first phase," Skvortsova told news agency TASS. She added that all stages of testing and

'I’m a positive person and I don’t really focus on the potential downsides here. I wasn’t scared. My friends were like, "You need to be a little more scared about it."' 

Haller was among the 45 volunteers who were selected for the potential COVID-19 vaccine trial at the Kaiser Permanente Washington Research Institute in Seattle.  

The injection has been developed in record time after the new virus exploded from China and fanned across the globe.

'We're team coronavirus now,' Kaiser Permanente study leader Dr. Lisa Jackson said on the eve of the experiment. 'Everyone wants to do what they can in this emergency.' 

Haller received her first vaccine injection on Monday morning. Three others were next in line for a test that will ultimately give 45 volunteers two doses, a month apart. 

Monday's milestone marked just the beginning of a series of studies in people needed to prove whether the shots are safe and could work. 

In pics: Coronavirus (COVID-19) outbreak around the world

Even if the research goes well, a vaccine would not be available for widespread use for 12 to 18 months, said Dr. Anthony Fauci of the U.S. National Institutes of Health.

Still, finding a vaccine 'is an urgent public health priority,' Fauci said in a statement Monday. The new study, 'launched in record speed, is an important first step toward achieving that goal.'

This vaccine candidate, code-named mRNA-1273, was developed by the NIH and Massachusetts-based biotechnology company Moderna Inc. There is no chance participants could get infected from the shots because they do not contain the coronavirus itself.

It is not the only potential vaccine in the pipeline. Dozens of research groups around the world are racing to create a vaccine against COVID-19. Another candidate, made by Inovio Pharmaceuticals, is expected to begin its own safety study - in the U.S., China and South Korea - next month.

The Seattle experiment got underway days after the World Health Organization declared the new virus outbreak a pandemic because of its rapid global spread, infecting more than 169,000 people and killing more than 6,500.

COVID-19 has upended the world´s social and economic fabric since China first identified the virus in January, with regions shuttering schools and businesses, restricting travel, canceling entertainment and sporting events, and encouraging people to stay away from each other.

Starting what scientists call a first-in-humans study is a momentous occasion for scientists, but Jackson described her team´s mood as 'subdued.' They´ve been working round-the-clock readying the research in a part of the U.S. struck early and hard by the virus.

Still, 'going from not even knowing that this virus was out there ... to have any vaccine' in testing in about two months is unprecedented, Jackson said. 

Some of the study's carefully chosen healthy volunteers, ages 18 to 55, will get higher dosages than others to test how strong the inoculations should be. 

Scientists will check for any side effects and draw blood samples to test if the vaccine is revving up the immune system, looking for encouraging clues like the NIH earlier found in vaccinated mice.

'We don't know whether this vaccine will induce an immune response, or whether it will be safe. That´s why we´re doing a trial,' Jackson stressed. 'It´s not at the stage where it would be possible or prudent to give it to the general population.'

Most of the vaccine research under way globally targets a protein aptly named 'spike' that studs the surface of the new coronavirus and lets it invade human cells. Block that protein and people won´t get infected.

Researchers at the NIH copied the section of the virus' genetic code that contains the instructions for cells to create the spike protein. Moderna encased that 'messenger RNA' into a vaccine.

The idea: The body will become a mini-factory, producing some harmless spike protein. When the immune system spots the foreign protein, it will make antibodies to attack and be primed to react quickly if the person later encounters the real virus.

Also watch: Quarantined Italians dance on their balconies (Video by AFP)

That's a much faster way of producing a vaccine than the traditional approach of growing virus in the lab and preparing shots from either killed or weakened versions of it.

But because vaccines are given to millions of healthy people, it takes time to test them in large enough numbers to spot an uncommon side effect, cautioned Dr. Nelson Michael of the Walter Reed Army Institute of Research, which is developing a different vaccine candidate.

'The science can go very quickly but, first, do no harm, right?' he told reporters last week.

The Seattle research institute is part of a government network of centers that test all kinds of vaccines, and was chosen for the coronavirus vaccine study before COVID-19 began spreading widely in Washington state.

Kaiser Permanente screened dozens of people, looking for those who have no chronic health problems and aren´t currently sick. 

Researchers are not checking whether would-be volunteers already had a mild case of COVID-19 before deciding if they are eligible. 

If some did, scientists will be able to tell by the number of antibodies in their pre-vaccination blood test and account for that, Jackson said. Participants will be paid $100 for each clinic visit in the study.

11 questions about the coronavirus we still can’t answer .
Here’s what we don’t know about the coronavirus — and why it really matters.

usr: 1
This is interesting!